Business Context and Reporting Period
This Form 6-K filing by Pharming Group N.V. (Pharming) relates to a corporate transaction announced on February 7, 2025. The filing discloses the completion of a recommended cash offer by Pharming Technologies B.V. (a wholly-owned subsidiary) to acquire Abliva AB (publ). The document serves as a regulatory update regarding the tender offer status, acceptance levels, and subsequent procedural steps.
Key Financial Metrics and Transaction Details
The filing focuses on the terms of the acquisition rather than Pharming's operational financial performance (revenue, profit, or cash flow) for the period.
- Offer Price: SEK 0.45 in cash per share of Abliva.
- Shares Accepted: 1,413,841,472 shares and votes.
- Acceptance Level: Approximately 87.7% of total issued shares and votes in Abliva.
- Warrant Acquisition: Pharming agreed to acquire 68,131,850 employee and board warrants at prices ranging from SEK 0.03 to SEK 0.054 per warrant, based on Black-Scholes valuation.
- Settlement Dates: Initial settlement expected around February 14, 2025; settlement for the extended period expected around February 27, 2025.
Material Changes and Transaction Status
The most significant development is the declaration of the Offer as unconditional. Although the original offer document stipulated a condition requiring acceptance of more than 90% of shares to complete the transaction, Pharming has exercised its right to waive this acceptance level condition. Consequently, the Offer is now complete for all tendered shares, and Pharming controls approximately 87.7% of Abliva. The acceptance period has been extended until February 20, 2025, to allow remaining shareholders to tender their shares.
Outlook, Management Commentary, and Risks
Future Actions: Pharming intends to initiate a compulsory acquisition procedure under the Swedish Companies Act if it acquires more than 90% of Abliva shares, which would facilitate the delisting of Abliva from Nasdaq Stockholm.
Risks and Contingencies:
- Regulatory Jurisdiction: The offer is subject to Swedish law and may differ from U.S. customary practices. U.S. shareholders may face difficulties enforcing rights under U.S. securities laws in non-U.S. courts.
- Tax Implications: Acceptance of the offer may constitute a taxable event for U.S. federal and state income tax purposes.
- Forward-Looking Statements: The filing includes standard disclaimers that future performance and the benefits of the offer are subject to risks and uncertainties.
Key Facts for Investor Verification
- Verify the final settlement date for shares tendered during the extended acceptance period (expected around February 27, 2025).
- Confirm the total consideration paid for the 68,131,850 warrants acquired outside the main share offer.
- Monitor announcements regarding the initiation of the compulsory acquisition procedure and the subsequent delisting of Abliva from Nasdaq Stockholm.
- Review the specific tax consequences for shareholders in their respective jurisdictions, particularly for U.S. holders receiving payment in SEK.